Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating perampanel as monotherapy or first adjunctive therapy for various seizure types in partial onset and generalized seizures; study comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Tonic-clonic Seizures
• Partial-onset Seizures
• Secondarily Generalized Seizures

Drugs mentioned

• Perampanel (perampanel)

Snippet

Sponsor: Eisai Inc. | Conditions: Partial Onset Seizures, Secondarily Generalized Seizures | Phase 4 | Status: COMPLETED | Results posted: 2022-05-16